If I read GSK's report correctly, then full years sales of Promacta were 130MM pounds sterling. Using today's conversion that is $204,100,000 ( 1:1.57$). That yeilds a 7.5% royalty rate, which is $15,307,500 in revenues for Ligand for the year 2012. They booked 6.4 MM in revenues for the 3rd quarter primarily from Promacta. Looks like a very nice quarter and good year forthcoming.